Use of human blood cells to assess therapeutic antibody efficacy
Research type
Research Study
Full title
Use of human blood cells to assess therapeutic antibody efficacy in activating immune cells
IRAS ID
338514
Contact name
Claire Seal
Contact email
Sponsor organisation
invoX Pharma
Duration of Study in the UK
5 years, 0 months, 1 days
Research summary
We wish to obtain leukocyte cones or whole blood from either the NHSBT Non-Clinical Issue stream, or from commercial providers if availability is an issue. We will isolate PBMCs from the samples, and use these to test the ability of our proprietary antibodies to activate the T-cells, to assess how effective the antibodies may be at triggering immune-mediated elimination of cancer cells.
REC name
West Midlands - Solihull Research Ethics Committee
REC reference
23/WM/0278
Date of REC Opinion
20 Dec 2023
REC opinion
Favourable Opinion